|
Wilson, Wyndham H; Dunleavy, Kieron; Pittaluga, Stefania et al. (2008) Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 26:2717-24
|
|
Dunleavy, Kieron; Staudt, Louis M; Wilson, Wyndham H (2007) The BCL-2 biomarker in the era of molecular diagnosis of diffuse large B-cell lymphoma. Leuk Lymphoma 48:1061-3
|
|
Dunleavy, Kieron; Wilson, Wyndham H; Jaffe, Elaine S (2007) Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications. Curr Opin Hematol 14:348-53
|
|
Dunleavy, Kieron; Wilson, Wyndham H (2007) Angioimmunoblastic T-cell lymphoma: immune modulation as a therapeutic strategy. Leuk Lymphoma 48:449-51
|
|
Wiestner, Adrian; Tehrani, Mahsa; Chiorazzi, Michael et al. (2007) Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood 109:4599-606
|
|
Dunleavy, Kieron; Davis, R Eric; Landgren, Ola et al. (2007) BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we? Blood 109:843-4;discussion 844-5
|
|
Dunleavy, Kieron; Hakim, Frances; Kim, Hyun Kyung et al. (2005) B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 106:795-802
|
